P. Miossec

1.3k total citations
22 papers, 1.1k citations indexed

About

P. Miossec is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, P. Miossec has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Molecular Biology and 6 papers in Surgery. Recurrent topics in P. Miossec's work include Diabetes Management and Research (9 papers), Diabetes Treatment and Management (8 papers) and Metabolism, Diabetes, and Cancer (5 papers). P. Miossec is often cited by papers focused on Diabetes Management and Research (9 papers), Diabetes Treatment and Management (8 papers) and Metabolism, Diabetes, and Cancer (5 papers). P. Miossec collaborates with scholars based in France, United States and Germany. P. Miossec's co-authors include Julio Rosenstock, D. Raccah, John E. Gerich, Ronnie Aronson, Elisabeth Niemoeller, Stéphane Saubadu, Bo Åhrén, László Korányi, Laura Maffei and Matthew C. Riddle and has published in prestigious journals such as Diabetes Care, International Journal of Obesity and Metabolism.

In The Last Decade

P. Miossec

21 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Miossec France 12 991 455 376 204 83 22 1.1k
Andrei‐Mircea Catarig Denmark 17 899 0.9× 623 1.4× 171 0.5× 241 1.2× 115 1.4× 30 1.0k
Marilyn K. Boardman United States 10 1.0k 1.0× 470 1.0× 358 1.0× 275 1.3× 84 1.0× 12 1.1k
Michaël J.B. van Baar Netherlands 7 656 0.7× 233 0.5× 311 0.8× 108 0.5× 53 0.6× 12 773
Charles Atisso United States 7 812 0.8× 465 1.0× 253 0.7× 244 1.2× 84 1.0× 18 864
Rimma M. Shaginian United States 6 893 0.9× 416 0.9× 404 1.1× 157 0.8× 90 1.1× 8 947
Valentina Lukashevich United States 14 908 0.9× 250 0.5× 269 0.7× 106 0.5× 39 0.5× 17 1.1k
Jakob Werner Germany 5 537 0.5× 181 0.4× 300 0.8× 80 0.4× 90 1.1× 8 654
Bryan Goldman Denmark 7 415 0.4× 203 0.4× 116 0.3× 208 1.0× 73 0.9× 11 514
S Rilli Italy 8 425 0.4× 114 0.3× 199 0.5× 89 0.4× 73 0.9× 12 595
Hakki Bölükoglu United States 8 522 0.5× 263 0.6× 219 0.6× 80 0.4× 70 0.8× 13 770

Countries citing papers authored by P. Miossec

Since Specialization
Citations

This map shows the geographic impact of P. Miossec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Miossec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Miossec more than expected).

Fields of papers citing papers by P. Miossec

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Miossec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Miossec. The network helps show where P. Miossec may publish in the future.

Co-authorship network of co-authors of P. Miossec

This figure shows the co-authorship network connecting the top 25 collaborators of P. Miossec. A scholar is included among the top collaborators of P. Miossec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Miossec. P. Miossec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Byrne, Barry J., Pierre G. Carlier, John Vissing, et al.. (2024). NEO1/NEO-EXT studies: Long-term muscle quantitative magnetic resonance imaging and functional efficacy in adults with late-onset Pompe disease (LOPD) on avalglucosidase alfa treatment. Molecular Genetics and Metabolism. 141(2). 107783–107783. 1 indexed citations
2.
Boentert, Matthias, Shahram Attarian, Jordi Díaz‐Manera, et al.. (2023). Post-hoc Nonparametric Analysis of Forced Vital Capacity in the COMET Trial Demonstrates Superiority of Avalglucosidase Alfa vs Alglucosidase Alfa. Journal of Neuromuscular Diseases. 11(2). 369–374. 2 indexed citations
3.
Díaz‐Manera, Jordi, Mazen M. Dimachkie, Emmanuelle Salort‐Campana, et al.. (2023). Nonparametric analysis of forced vital capacity in the COMET trial demonstrates superiority of avalglucosidase alfa vs alglucosidase alfa. Molecular Genetics and Metabolism. 138(2). 107077–107077. 1 indexed citations
4.
Tiraboschi, Gilles, Gilles Tuffal, David Fabre, et al.. (2023). Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease. Journal of Pharmacokinetics and Pharmacodynamics. 50(6). 461–474. 4 indexed citations
5.
Garg, Satish K., Karin Wernicke‐Panten, Marek Wardęcki, et al.. (2020). Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial. Diabetes Technology & Therapeutics. 22(7). 516–526. 7 indexed citations
6.
Christensen, Mikkel, P. Miossec, Bjarne Due Larsen, Werner Ulrich, & Filip K. Knop. (2014). The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. Expert Opinion on Drug Discovery. 9(10). 1223–1251. 25 indexed citations
7.
8.
9.
10.
Riddle, Matthew C., Ronnie Aronson, Philip Home, et al.. (2013). Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin. Diabetes Care. 36(9). 2489–2496. 247 indexed citations
11.
Rosenstock, Julio, D. Raccah, László Korányi, et al.. (2013). Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin. Diabetes Care. 36(10). 2945–2951. 211 indexed citations
12.
Miossec, P., et al.. (1999). Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled Type 2 diabetic patients. Diabetic Medicine. 16(5). 424–430. 19 indexed citations
13.
Miossec, P., B. Lormeau, P. Valensi, et al.. (1999). Bone amyloidoma in a diabetic patient with morbid obesity.. PubMed. 25(3). 261–3. 13 indexed citations
14.
Valensi, P., et al.. (1998). Glucose-induced thermogenesis, inhibition of lipid oxidation rate and autonomic dysfunction in non-diabetic obese women. International Journal of Obesity. 22(6). 494–499. 15 indexed citations
15.
Valensi, P., Thị Nhạn Nguyễn, Gholamreza Asadi Karam, et al.. (1998). Influence of parasympatheitc dysfunction and hyperinsulinemia on the hemodynamic response to an isometric exercise in non—insulin-dependent diabetic patients. Metabolism. 47(8). 934–939. 20 indexed citations
16.
Miossec, P., et al.. (1997). [Inhibition of steroidogenesis by ketoconazole. Therapeutic uses].. PubMed. 58(6). 494–502. 9 indexed citations
17.
Lormeau, B., P. Miossec, Mathilde Sibony, P. Valensi, & JR Attali. (1997). Adrenocorticotropin-producing pituitary carcinoma with liver metastasis. Journal of Endocrinological Investigation. 20(4). 230–236. 28 indexed citations
18.
Lormeau, B., et al.. (1997). [The "short Achilles tendon" syndrome: a new entity of the diabetic foot].. PubMed. 23(5). 443–7. 1 indexed citations
19.
Valensi, P., et al.. (1995). [Gastric emptying and diabetic instability].. PubMed. 257–70. 1 indexed citations
20.
Miossec, P., et al.. (1992). [Hashimoto's disease and hyperthyroidism].. PubMed. 143(1). 69–70.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrei‐Mircea Catarig Breakdown of academic impact, for papers by Marilyn K. Boardman Breakdown of academic impact, for papers by Michaël J.B. van Baar Breakdown of academic impact, for papers by Charles Atisso Breakdown of academic impact, for papers by Rimma M. Shaginian Breakdown of academic impact, for papers by Valentina Lukashevich Breakdown of academic impact, for papers by Jakob Werner Breakdown of academic impact, for papers by Bryan Goldman Breakdown of academic impact, for papers by S Rilli Breakdown of academic impact, for papers by Hakki Bölükoglu
Rankless by CCL
2026